ELF in PsA version 1.0

• Research type

  Research Study

• Full title

  Evaluation of Liver Fibrosis in Psoriatic Arthritis

• IRAS ID

  181181

• Contact name

  John P Harvie

• Contact email

  john.harvie@nhs.net

• Sponsor organisation

  NHS Highland

• Duration of Study in the UK

  0 years, 11 months, 31 days

• Research summary

  Methotrexate is the commonest disease modifying drug (DMARD) used in psoriatic arthritis (PsA) but it is known that it can rarely be associated with the development of liver cirrhosis(fibrosis). There are many other factors which can contribute liver fibrosis in these patients.
  Patients will have a targeted history, blood sampling and Fibroscan ultrasound.
  The study's primary objective is to assess the incidence of liver fibrosis, as determined by Fibroscan(special ultrasound), in a cohort of patients with psoriatic arthritis who attend the rheumatology clinic at Raigmore Hospital. I wish then to determine which is the most sensitive blood test for accurately assess the presence of liver fibrosis. I also wish to identify which patient characteristics contribute to an increased risk of fibrotic changes.

  
  

• REC name

  North of Scotland Research Ethics Committee 1

• REC reference

  15/NS/0100

• Date of REC Opinion

  22 Mar 2016

• REC opinion

  Further Information Favourable Opinion